Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01067781 · ClinicalTrials.gov registry record · Phase 2

Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch

A Phase 2 study, sponsored by Intercell USA.

Completed
Registry status
Phase 2
Development phase
600
Enrollment target

NCT01067781: Completed Phase 2 study, sponsored by Intercell USA.

NCT01067781 is a Phase 2 study that has completed, run by Intercell USA. The registered enrollment target is 600 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01067781, a Phase 2 study, has completed, sponsored by Intercell USA.

COMPLETED
Registry status
Phase 2
Development phase
600 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate and compare the safety and immune responses following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or Placebo, with or without alcohol swabbing

Primary Outcome

Erythema, rash, pain, pruritus, hyperpigmentation, hypopigmentation and edema were solicited local AEs for the duration of the study. Fever, malaise, headache, and diarrhea were solicited systemic AEs for the first seven days following each vaccination; events reported outside this time frame were considered non-solicited.

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL Heat-Labile Enterotoxin of E. coli (LT)

Trial Details

FieldValue
Enrollment Target 600 participants
Start Date 2010-02
Est. Completion 2012-03
Phase Phase 2
Intercell USA

7 total trials

What the finished NCT01067781 record still lists

NCT01067781 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (351% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01067781 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01067781 about?

NCT01067781 is a clinical study titled "Safety and Immunogenicity Study of Traveler's Diarrhea Vaccine Patch". The purpose of this study is to evaluate and compare the safety and immune responses following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or Placebo, with or without alcohol swabbing

What is the current status of trial NCT01067781?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2010-02. Estimated completion is 2012-03.

What interventions are being tested in trial NCT01067781?

The interventions under investigation include: Placebo (BIOLOGICAL), Heat-Labile Enterotoxin of E. coli (LT) (BIOLOGICAL).

Who is sponsoring clinical trial NCT01067781?

This trial is sponsored by Intercell USA, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01067781's enrollment target sits among peer trials

600 53rd of 2000 higher than 1,945 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004317 · 600 participants · Phase 4

    Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

  • NCT00209235 · 600 participants · NA

    Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments

  • NCT01473784 · 600 participants · NA

    Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck

  • NCT01866371 · 600 participants

    High Resolution Retinal Imaging

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01067781, the US trial registry maintained by the National Library of Medicine. NCT01067781 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.